bioAffinity Technologies, Inc. (BIAF) vs Cadrenal Therapeutics, Inc. Common Stock (CVKD)

A side-by-side comparison of bioAffinity Technologies, Inc. and Cadrenal Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
bioAffinity Technologies, Inc. logo
BIAF
bioAffinity Technologies, Inc.
$3M
$6.19HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Cadrenal Therapeutics, Inc. Common Stock logo
CVKD
Cadrenal Therapeutics, Inc. Common Stock
$3M
$0.95HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — BIAF vs CVKD

growth of $100 · dividends reinvested · last 4y
BIAF -99.1% (-69.2%/yr)CVKD -98.5% (-64.8%/yr)CVKD compounded faster over this window
050100150200Start $100202420252026$1$2
BIAF CVKD

BIAF vs CVKD: by the numbers

  • •CVKD is the larger company ($3M vs $3M market cap).
  • •Both run net losses; CVKD's is the smaller (0.00% vs -257.33% net margin).

Metrics side by side

Valuation

MetricBIAFCVKD
P/S ratio0.44N/A
P/B ratio0.690.82

Profitability

MetricBIAFCVKD
Gross margin23.21%0.00%
Operating margin-171.58%0.00%
Net margin-257.33%0.00%
ROE-402.92%-282.13%
ROIC-237.93%-284.81%

Go deeper

Full BIAF analysisFull CVKD analysisInteractive comparison tool

Dig into the metrics

bioAffinity Technologies ROECadrenal Therapeutics, Inc. Common Stock ROEbioAffinity Technologies operating marginCadrenal Therapeutics, Inc. Common Stock operating marginbioAffinity Technologies revenue growthCadrenal Therapeutics, Inc. Common Stock revenue growthbioAffinity Technologies free cash flowCadrenal Therapeutics, Inc. Common Stock free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.